# Alector

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/alector

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.alector.com
- Total disclosed funding: $195M
- Latest round: Series E (Jul 25, 2018)
- Investors on record: 18

## About

Alector Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, including Alzheimer’s and ALS, with the aim of transforming treatment paradigms through advanced science and proprietary technologies.Alector Inc. was founded in 2013 in San Francisco, US, by Arnon Rosenthal and Errik Anderson. The company specializes in therapeutic innovation for neurodegenerative diseases. It has successfully closed 6 deals, with its most recent funding round being an IPO on February 6, 2019, raising USD 175.75 mn, which comprised the total amount raised by the firm. Arnon Rosenthal serves as the CEO.Alector Therapeutics specializes in developing therapies aimed at neurodegenerative diseases, including frontotemporal dementia, Alzheimer’s, and ALS. Its core products focus on removing toxic proteins, replacing deficient proteins, and restoring immune and nerve cell function, utilizing advanced technologies like the Alector Brain Carrier (ABC) for targeted drug delivery across the blood-brain barrier. The company primarily targets the U.S. market while also exploring international opportunities.In 2024, Alector Inc. reported revenue of USD 100.56 mn. The company generated revenue through licensing agreements and collaborations within the biotechnology and pharmaceutical sectors, focusing on advancing its therapeutic candidates and ensuring successful commercialization.Alector plans to leverage its recent IPO funding to support the development of new therapeutic candidates and expand its market reach. The company is actively designing new products targeting neurodegenerative conditions and intends to penetrate additional markets within the next few years. Recent funding will provide the necessary capital for clinical trials and further research to enhance its product pipeline.

## Funding rounds

- Series E, Jul 25, 2018, $133M — OrbiMed Advisors, Polaris Partners, SV Health Investors, Amgen Ventures, New Leaf Venture Partners, Lilly Asia Ventures, Merck Global Health Innovation Fund, GV, Mission Bay Capital, Foresite Capital, Casdin Capital, AbbVie Ventures, Deerfield Management, Perceptive Advisors, Euclidean Capital, Section 32, Federated Investors
- Series D, Jan 7, 2016, $30M — OrbiMed Advisors, Polaris Partners, SV Health Investors, Amgen Ventures, Topspin Partners, Merck Global Health Innovation Fund, GV, Mission Bay Capital, AbbVie Ventures
- Series C, Sep 16, 2015, $32M — OrbiMed Advisors, Polaris Partners, Topspin Partners, Merck Global Health Innovation Fund, GV, Mission Bay Capital
- Series A, Oct 31, 2013 — OrbiMed Advisors, Polaris Partners

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series C, Series D, Series E
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series C, Series D, Series E
- Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series C, Series D
- Merck Global Health Innovation Fund (https://capitalatlas.ai/funds/merck-global-health-innovation-fund) — Series C, Series D, Series E
- GV (https://capitalatlas.ai/funds/gv) — Series C, Series D, Series E
- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series C, Series D, Series E
- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series D, Series E
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series D, Series E
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series D, Series E
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series E
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series E
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series E
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series E
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series E
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series E
- Euclidean Capital — Series E
- Section 32 (https://capitalatlas.ai/funds/section-32) — Series E
- Federated Investors — Series E